{"nctId":"NCT00740051","briefTitle":"A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate","startDateStruct":{"date":"2008-08"},"conditions":["Diabetes Mellitus, Type 2"],"count":227,"armGroups":[{"label":"Linagliptin","type":"EXPERIMENTAL","interventionNames":["Drug: Linagliptin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Linagliptin Placebo"]},{"label":"Glimepiride","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Glimepiride"]}],"interventions":[{"name":"Linagliptin","otherNames":[]},{"name":"Linagliptin Placebo","otherNames":[]},{"name":"Glimepiride","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria Patients between 18 and 80 years old with type 2 diabetes and insufficient glycemic control (HbA1c 7% to 10%) for whom metformin therapy is inappropriate (intolerability or contraindication)\n\nExclusion criteria Myocardial infarction, stroke or Transient ischaemic attack in last 6 months Treatment with rosiglitazone or pioglitazone, GLP-1 analogues, insulin or anti-obesity drugs in past 3 months Impaired hepatic function Severe renal impairment current treatment with systemic steroids change in dosage of thyroid hormones hereditary galactose intolerance","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"HbA1c Change From Baseline at Week 18 (Interim Analysis)","description":"HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 18 HbA1c percent minus the Week 0 HbA1c percent. Means are adjusted for baseline HbA1c, prior OADs and reason for metformin intolerance.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.14","spread":"0.16"},{"groupId":"OG001","value":"-0.44","spread":"0.14"}]}]}]},{"type":"PRIMARY","title":"HbA1c Change From Baseline at Week 18 (Final Analysis)","description":"HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 18 HbA1c percent minus the Week 0 HbA1c percent. Means are adjusted for baseline HbA1c, prior OADs and reason for metformin intolerance. HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 18 HbA1c percent minus the Week 0 HbA1c percent. Means are adjusted for baseline HbA1c, prior OADs and reason for metformin intolerance. The primary analysis was re-run at the completion of the study in the final study report.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.21","spread":"0.16"},{"groupId":"OG001","value":"-0.39","spread":"0.14"}]}]}]},{"type":"SECONDARY","title":"Fasting Plasma Glucose (FPG) Change From Baseline at Week 18 (Interim Analysis)","description":"This change from baseline reflects the Week 18 FPG minus the Week 0 FPG. Means are adjusted for baseline FPG, baseline HbA1c, prior OADs and reason for metformin intolerance (Interim Analysis).","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":"6.0"},{"groupId":"OG001","value":"-13.3","spread":"5.2"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With HbA1c<7.0 at Week 18 (Interim Analysis)","description":"Odds ratios are adjusted for baseline HbA1c, prior OADs and reason for metformin intolerance.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8","spread":null},{"groupId":"OG001","value":"23.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With HbA1c<6.5 at Week 18 (Interim Analysis)","description":"Odds ratios are adjusted for baseline HbA1c, prior OADs and reason for metformin intolerance.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null},{"groupId":"OG001","value":"8.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With HbA1c Lowering by 0.5% at Week 18 (Interim Analysis)","description":"Odds ratios are adjusted for baseline HbA1c, prior OADs and reason for metformin intolerance.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.8","spread":null},{"groupId":"OG001","value":"36.1","spread":null}]}]}]},{"type":"SECONDARY","title":"The Change in HbA1c From Baseline by Visit Over Time","description":"HbA1c is measured as a percentage. Thus, this change from baseline reflects the HbA1c percent (at weeks 6, 12, 18, 22, 26, 30, 34, 40, 46, 52) minus the Week 0 HbA1c percent.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.26","spread":"0.98"},{"groupId":"OG001","value":"-0.21","spread":"0.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.26","spread":"1.08"},{"groupId":"OG001","value":"-0.43","spread":"0.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","spread":"1.06"},{"groupId":"OG001","value":"-0.38","spread":"0.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.32","spread":"0.82"},{"groupId":"OG001","value":"-0.40","spread":"0.94"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.53","spread":"0.93"},{"groupId":"OG001","value":"-0.48","spread":"0.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.79","spread":"1.06"},{"groupId":"OG001","value":"-0.49","spread":"0.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.75","spread":"0.95"},{"groupId":"OG001","value":"-0.49","spread":"0.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.73","spread":"1.11"},{"groupId":"OG001","value":"-0.45","spread":"0.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.78","spread":"1.04"},{"groupId":"OG001","value":"-0.42","spread":"0.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.72","spread":"1.01"},{"groupId":"OG001","value":"-0.44","spread":"1.00"}]}]}]},{"type":"SECONDARY","title":"The Change in FPG From Baseline by Visit Over Time","description":"This change from baseline reflects the FPG (at weeks 6, 12, 18, 22, 26, 30, 34, 40, 46, 52) minus the Week 0 FPG.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.7","spread":"30.7"},{"groupId":"OG001","value":"-8.4","spread":"41.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":"33.0"},{"groupId":"OG001","value":"-14.3","spread":"37.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":"32.4"},{"groupId":"OG001","value":"-12.9","spread":"35.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.3","spread":"33.3"},{"groupId":"OG001","value":"-14.0","spread":"41.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.6","spread":"33.8"},{"groupId":"OG001","value":"-17.0","spread":"37.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-31.4","spread":"29.5"},{"groupId":"OG001","value":"-19.1","spread":"39.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-25.6","spread":"35.2"},{"groupId":"OG001","value":"-15.8","spread":"36.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.5","spread":"33.2"},{"groupId":"OG001","value":"-19.0","spread":"36.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.8","spread":"32.3"},{"groupId":"OG001","value":"-18.1","spread":"38.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.1","spread":"30.1"},{"groupId":"OG001","value":"-14.0","spread":"37.1"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":76},"commonTop":["Hyperglycaemia","Nasopharyngitis","Dizziness","Headache","Upper respiratory tract infection"]}}}